Ignite Creation Date:
2024-10-26 @ 3:39 PM
Last Modification Date:
2024-10-26 @ 3:39 PM
Study NCT ID:
NCT06590415
Status:
NOT_YET_RECRUITING
Last Update Posted:
None
First Post:
2024-09-03
Brief Title:
Trancriptomics and Lipidomics of Epicardial Ectopic Fat
Sponsor:
None
Organization:
None
Study Overview
Official Title:
Trancriptomics and Lipidomics of Epicardial Ectopic Fat
Status:
NOT_YET_RECRUITING
Status Verified Date:
2024-09
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
GENTLE
Brief Summary:
Cohort studies have shown that patients with obesity associated with metabolic abnormalities metabolically unhealthy obesity have an accumulation of ectopic fat deposits EDF linked to subcutaneous adipose tissue dysfunction Although it is accepted that the storage capacity of subcutaneous adipose tissue is genetically determined the genetic factors predisposing to adipose tissue distribution abnormalities remain poorly understood
The Angiosafe T2D cohort consists of 7200 highly phenotyped type 2 diabetes T2D patients In 297 patients from this cohort ancillary study investigators assessed epicardial fat volume EFV using an artificial intelligence algorithm In 42 of these patients designated as early T2DMDGE an accumulation of epicardial fat and diabetes occurring before the age of 40 were observed clinically approaching the clinical presentation of genetic lipodystrophy although subcutaneous adipose tissue persisted in their case
This study will focus on a case-control study nested within the pre-existing cohort of T2D patients Angiosafe T2D and more specifically within this cohort on a subgroup of 42 patients with early-onset diabetes and an abnormal distribution of adipose tissue caracterized by ectopic fat accumulation In order to understand the severe metabolic phenotype observed in this group of 42 patients investigators propose to perform a multiomic analysis combining clinico-biological exomic transcriptomic and lipidomic data
This study will compare the rate of patients with at least one rare lt1 general population potentially pathogenic genetic variant in a coding region of the genetic lipodystrophy genes by whole exome sequencing in 42 early-onset T2DM and a high epicardial fat volume patients versus 42 patients without early-onset T2DM andor high epicardial fat volume control group
The Angiosafe T2D cohort consists of 7200 highly phenotyped type 2 diabetes T2D patients In 297 patients from this cohort ancillary study investigators assessed epicardial fat volume EFV using an artificial intelligence algorithm In 42 of these patients designated as early T2DMDGE an accumulation of epicardial fat and diabetes occurring before the age of 40 were observed clinically approaching the clinical presentation of genetic lipodystrophy although subcutaneous adipose tissue persisted in their case
This study will focus on a case-control study nested within the pre-existing cohort of T2D patients Angiosafe T2D and more specifically within this cohort on a subgroup of 42 patients with early-onset diabetes and an abnormal distribution of adipose tissue caracterized by ectopic fat accumulation In order to understand the severe metabolic phenotype observed in this group of 42 patients investigators propose to perform a multiomic analysis combining clinico-biological exomic transcriptomic and lipidomic data
This study will compare the rate of patients with at least one rare lt1 general population potentially pathogenic genetic variant in a coding region of the genetic lipodystrophy genes by whole exome sequencing in 42 early-onset T2DM and a high epicardial fat volume patients versus 42 patients without early-onset T2DM andor high epicardial fat volume control group
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None